Ambalal Sarabhai Enterprises Ltd vs Kilitch Drugs India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Ambalal Sarabhai Enterprises Ltd is ₹ 31.26 as of 18 May 15:30 . The P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 yearsThe P/E Ratio of Kilitch Drugs (India) Ltd changed from 34.2 on March 2021 to 21.8 on March 2025 . This represents a CAGR of -8.61% over 5 years The Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 yearsThe Market Cap of Kilitch Drugs (India) Ltd changed from ₹ 125.58 crore on March 2021 to ₹ 581.3 crore on March 2025 . This represents a CAGR of 35.86% over 5 years The revenue of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 54.76 crore. This represent the decline of -100% The revenue of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 90.1 crore as compare to the Dec '25 revenue of ₹ 55.34 crore. This represent the growth of 62.81% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 6.02 crore. This represent the decline of -100% The ebitda of Kilitch Drugs (India) Ltd for the Mar '26 is ₹ 22.64 crore as compare to the Dec '25 ebitda of ₹ 7.68 crore. This represent the growth of 194.79% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Kilitch Drugs (India) Ltd changed from ₹ 0.11 crore to ₹ 14.88 crore over 8 quarters. This represents a CAGR of 1063.07% The Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Kilitch Drugs (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

About Kilitch Drugs (India) Ltd

Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range of pharmaceutical formulations in the various dosage forms like Solid, Liquid and Parental across the globe.
Their extensive research efforts have led to development of comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments which includes Sterile dosages namely Injectables & Ophthalmic, Effervescent tablets & Granules, Tablets & Capsules, OTC range covering varied Nutraceuticals & Cosmetics and Medical devices. The Company is engaged in development, manufacturing and marketing of quality finished dosages.
The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia.

FAQs for the comparison of Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd

Which company has a larger market capitalization, Ambalal Sarabhai Enterprises Ltd or Kilitch Drugs (India) Ltd?

Market cap of Ambalal Sarabhai Enterprises Ltd is 239 Cr while Market cap of Kilitch Drugs (India) Ltd is 593 Cr

What are the key factors driving the stock performance of Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd?

The stock performance of Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd?

As of May 18, 2026, the Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.26. On the other hand, Kilitch Drugs (India) Ltd stock price is INR ₹169.65.

How do dividend payouts of Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd compare?

To compare the dividend payouts of Ambalal Sarabhai Enterprises Ltd and Kilitch Drugs (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.